At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 10,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 5
- ✓Rare cancer with incidence less than 6 per 100,000 persons per year
- ✓Rare subtype of a more common cancer entity
- ✓Metastatic and/or locally advanced cancer
- ✓No curative therapy option available
Key exclusion· 1
- ✕Severe neurological or psychiatric disorder interfering with ability to provide informed consent
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research
In Brief
An observational study for Rare Cancers and Multiomics. Currently recruiting, targeting 10,000 participants across 1 site.
Detailed Summary
NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRare Cancers, Multiomics
CountriesGermany
CollaboratorsGerman Consortium for Translational Cancer Research
Timeline
N/ARecruiting
201920202021202220232024202520262027202820292030
Enrollment StartNov 2018
First PostedMay 2023
TodayJul 2026
Primary CompletionOct 2028
Study CompletionOct 2029
First PostedMay 10, 2023
Enrollment StartNov 11, 2018
Primary CompletionOct 1, 2028
Study CompletionOct 1, 2029
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 3.1 years agoPrimary completion in 2.2 years